DRTG(600329)2024-10-30 08:27Financial Performance - Total revenue for Q3 2024 was ¥1,646,191,771.12, a decrease of 3.43% compared to the same period last year[2] - Net profit attributable to shareholders was ¥146,136,561.08, an increase of 7.69% year-on-year[2] - Net profit excluding non-recurring items was ¥132,928,496.57, up 2.46% from the previous year[2] - Operating profit for the first three quarters of 2024 was CNY 919,432,930.61, compared to CNY 961,951,114.63 in 2023, indicating a decline of 4.42%[20] - Net profit for the first three quarters of 2024 was CNY 793,134,205.47, down from CNY 842,024,243.32 in 2023, representing a decrease of 5.79%[20] - The net profit attributable to the parent company for Q3 2024 is approximately ¥803.86 million, a decrease from ¥858.19 million in Q3 2023, representing a decline of about 6.3%[21] - The total comprehensive income for Q3 2024 is approximately ¥792.45 million, compared to ¥842.86 million in Q3 2023, indicating a decrease of around 5.9%[21] - Basic and diluted earnings per share for Q3 2024 are both ¥1.04, a decrease from ¥1.11 in Q3 2023, reflecting a decline of about 6.3%[21] Cash Flow and Investments - Operating cash flow for the quarter was ¥12,394,444.80, a significant increase of 130.05% compared to the same period last year[3] - Cash flow from operating activities for the first nine months of 2024 is approximately ¥6.20 billion, slightly down from ¥6.20 billion in the same period of 2023[22] - The net cash flow from operating activities for the first nine months of 2024 is approximately ¥567.61 million, a significant increase from ¥81.18 million in the same period of 2023[22] - Cash outflow from investing activities for the first nine months of 2024 is approximately ¥1.39 billion, compared to ¥713.65 million in the same period of 2023, indicating a substantial increase in investment spending[23] - The net cash flow from financing activities for the first nine months of 2024 is approximately -¥31.52 million, an improvement from -¥377.51 million in the same period of 2023[23] Assets and Liabilities - Total assets increased to ¥10,969,529,949.24, reflecting a growth of 7.23% from the end of the previous year[3] - Total assets as of the end of the third quarter of 2024 amounted to CNY 10,969,529,949.24, an increase of 7.25% from CNY 10,230,100,940.68 at the end of 2023[19] - Total liabilities as of the end of the third quarter of 2024 were CNY 4,515,635,865.06, up from CNY 3,584,864,433.55 in 2023, reflecting an increase of 25.92%[19] - The company's cash and cash equivalents at the end of the third quarter of 2024 were CNY 1,023,295,255.00, significantly higher than CNY 81,800,000.00 at the end of 2023[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,429, with the largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., holding 331,120,528 shares, representing 42.994% of the total[10] - The company has a significant shareholder structure, with ABN AMRO CLEARING BANK N.V. holding 72,878,700 shares, accounting for 9.463%[10] - The total number of shares held by the top ten shareholders includes 325,855,528 shares of unrestricted circulating stock[12] - The company reported no significant changes in the shareholder structure due to securities lending activities[15] Operational Metrics - The company's industrial segment revenue reached ¥3.59 billion, a year-on-year increase of 4.3%, while the commercial segment revenue was ¥2.33 billion, down 14.5%[7] - Research and development expenses for the first three quarters of 2024 were CNY 98,797,435.21, compared to CNY 86,494,285.36 in 2023, marking an increase of 14.00%[20] - The company reported a decrease in sales expenses to CNY 1,475,052,433.95 in 2024 from CNY 1,454,601,997.58 in 2023, a slight reduction of 1.40%[20] - Deferred income tax assets increased to CNY 301,856,506.84 in 2024 from CNY 265,992,670.23 in 2023, an increase of 13.48%[19] Cash and Cash Equivalents - The company's cash and cash equivalents as of September 30, 2024, amount to approximately CNY 1.45 billion, a decrease from CNY 2.13 billion at the end of 2023[17] - Cash and cash equivalents at the end of Q3 2024 amount to approximately ¥1.36 billion, down from ¥1.93 billion at the end of Q3 2023[23] - Cash and cash equivalents decreased by 31.55% due to increased cash payments for large deposits[9] Government Subsidies - The company received government subsidies amounting to ¥1,723,185.35 during the reporting period[5] Other Information - The company has not disclosed any new strategies or product developments during the reporting period[16] - The company has not participated in margin trading or securities lending activities during the reporting period[13]